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While semaphorins and their receptors appear to play a role in tumor carcinogenesis, little is known about the role of semaphorin
3F (S3F) in epithelial ovarian cancer (EOC) development. Therefore, we sought to determine the clinical relationship between
S3F and its receptors, neuropilin-2 (NP-2) and neuropilin-1 (NP-1) with EOC progression. We analyzed the immunohistological
expression of S3F, NP-2, and NP-1 in clinical specimens of normal ovaries (N), benign cystadenomas (Cy), well-diﬀerentiated
adenocarcinomas (WD), poorly-diﬀerentiated adenocarcinomas (PD), inclusion cysts (IC), paraovarian cysts (PC), and fallopian
tubes (FT). Tissue sections were evaluated for staining intensity and percentage of immunoreactive epithelia. We found that
expressionofS3FandNP-2decreasedwhileNP-1expressionincreasedwithEOCprogression.Interestingly,wealsofoundelevated
expression of S3F, NP-2, and NP-1 in epithelia of ICs, PCs, and FT. Our ﬁndings indicate that loss or deregulation of semaphorin
signaling may play an important role in EOC development.
Copyright © 2009 Christina D. Drenberg et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Epithelial ovarian cancer (EOC) is the most lethal and
the second most commonly diagnosed gynecological malig-
nancy. It is estimated that in 2009, it will strike over 21000
women seventy percent of whom will be ﬁrst diagnosed
at advanced stages and will die within ﬁve years [1]. In
general, EOC is characterized by poor prognosis due to lack
of early symptoms, which contributes to advanced stage
of disease at presentation, and by the absence of accurate
screening methods to detect early stages of the disease. The
origin of this malignancy has been traditionally attributed to
the ovarian surface epithelium (OSE). However, alternative
theories to a coelomic origin attribute the source of EOC
to primary or secondary M¨ ullerian system derivatives such
as the ﬁmbriated end of the fallopian tube and paraovarian
vestigial structures, respectively [2–4]. The M¨ ullerian system
theory would explain why epithelial ovarian neoplasms
present as morphological variants of fallopian tube (serous
adenocarcinoma), uterus (endometrioid), or endocervix
(mucinous adenocarcinoma) epithelia without requiring an
intermediate metaplastic step [4]. Independently of its cell
of origin, the pathogenesis of this most lethal gynecologic
m a l i g n a n c yi s ,h o w e v e r ,n o tw e l lu n d e r s t o o d .
Semaphorins are a large family of transmembrane,
secreted, or glycosylphosphatidylinositol (GPI) anchored,
proteins involved in axon guidance and growth cone collapse
through interaction with their receptors, the neuropilins and
plexins [5]. There are eight classes of semaphorin genes all
of which are characterized by a conserved 500 amino acid,2 Obstetrics and Gynecology International
cystine-rich Sema domain, which mediates binding speci-
ﬁcity and is necessary for signaling [5]. Plexins are trans-
membrane receptors that form complexes with neuropilin
transmembrane receptors and mediate signal transduction
following binding to a semaphorin [6]. Additional biolog-
ical functions for semaphorins and their receptors include
regulation of angiogenesis as well as tumor progression and
metastasis [5, 7].
With regard to angiogenesis, the class 3 semaphorins
are of interest since members of this class have demon-
strated either pro- or antitumorigenic functions. Class-3
semaphorins are unique in that they directly bind neuropilin
homo- or heterodimeric receptors and are unable to bind
directly to plexins [8–11]. However, signaling is regulated
throughanoligomericcomplexinvolvinganeuropilin dimer
and one of four type-A plexins [6, 12–14]. Interestingly,
neuropilins also function as coheteroreceptors with vascular
endothelial growth factor receptors for vascular endothelial
growth factor (VEGF), whose over expression contributes to
tumor growth and metastasis [15]. Of interest is semaphorin
3F (S3F), a class 3 secreted protein which plays a critical
role during neural development in both the peripheral and
central nervous systems through interaction with its high
aﬃnity receptor NP-2 and low-aﬃnity receptor NP-1 [13].
S3F has also been shown to inhibit angiogenesis by decreas-
ingbloodvesseldensityandthroughcompetitionwithVEGF
for a shared receptor complex [16, 17]. Speciﬁcally, S3F
induces a poorly vascularized, encapsulated, non-metastatic
phenotype through chemorepulsion of endothelial cells in
melanoma [18]. In breast cancer, S3F disrupts intercellular
contacts of MCF7 breast cancer cells through delocalization
of E-cadherin and β-catenin [7]. Further, S3F and VEGF
demonstrateopposingeﬀectsforcellattachmentandspread-
ing [19], as well as migration [20].
S3F loss or delocalization has been shown to correlate
with advanced tumor stage in a number of cancers including
lung and breast [21]; however, a correlation between S3F and
tumor stage, grade, and histological subtype remains to be
demonstrated in ovarian cancer. In order to begin to better
understand epithelial ovarian carcinogenesis, we sought to
determine the clinical relationship between S3F and EOC
progression. Therefore, we analyzed the immunohistochem-
ical expression of S3F and its two receptors NP-1 and NP-2
in clinical specimens.
2.MaterialsandMethods
2.1. Tissue Specimens. With institutional approval, 44 spec-
imens were retrieved from the tissue bank at H. Lee Moﬃtt
Cancer Center and Research Institute. Serial 4-5μms e c t i o n s
were hematoxylin and eosin stained and classiﬁed according
to FIGO criteria (International Federation of Gynecology
and Obstetrics) as normal ovaries (N, n = 12), benign
serous cystadenomas (Cy, n = 10), well-diﬀerentiated serous
cystadenocarcinomas (WD, n = 4), poorly diﬀerentiated
serous cystadenocarcinomas (PD, n = 6) and fallopian tubes
(FT, n = 4). Three of 4 WD carcinomas were late stage
(III-IV) whereas all PD specimens were of late stage. We
also evaluated epithelia of inclusion cysts (IC, n = 6) and
paraovarian cysts (PC, n = 2) from patients with otherwise
normal ovaries and fallopian tubes.
2.2. Immunohistochemistry. Immunohistochemical staining
was performed on serial paraﬃn-embedded sections by the
horseradish peroxidase (HRP) conjugated system using a
Dako Autostainer Plus (Dako NorthAmerica, Inc., Carpin-
teria, CA). Microwave antigen retrieval was achieved using
10x Antigen Retrieval AR-10 (Tris) (BioGenex, San Ramon,
CA) or 10mM citrate buﬀer for 17 minutes. Sections were
rinsed twice with deionized water, washed in Tris buﬀered
saline (TBS)/Tween for 5 minutes and immunostained on
the Dako Autostainer with the following: rabbit antiS3F
polyclonal antibody (Chemicon, Billerica, MA) at 1 : 50
for 1 hour at room temperature, rabbit antineuropilin-1
polyclonal antibody (ECM Biosciences, Versailles, KY) at
1 : 200 overnight at 4◦C, and the mouse antineuropilin-
2 monoclonal antibody (Santa Cruz Biotechnology, Inc.,
S a n t aC r u z ,C A )a t1:7 5f o r1h o u ra tr o o mt e m p e r a t u r e .
Secondary antibodies for S3F and NP-2 were Vector Elite
ABCPeroxidase,usingrabbitIgGandGoatIgG,respectively;
DAB was the chromogen. The secondary antibody for NP-1
was EnVision + Peroxidase polymer. Endogenous peroxidase
was blocked with 3% aqueous hydrogen peroxide. Sections
were counterstained with modiﬁed Mayer’s hematoxylin.
Immunostaining of S3F, NP-1, and NP-2 was evaluated
by two independent observers (SVN and CD) and scored
based on staining intensity from 1 to 3 (0; negative; 1;
weak; 2; moderate; and 3; strong) and percent of positive
epithelial cells (1; 1–10%; 2; 10–50%; and 3; >50%). Cellular
localization of S3F, NP-1, and NP-2 was also assessed. To
conﬁrmthespeciﬁcityoftheantibodies,non-immunerabbit
IgG and goat IgG were used as negative controls in place
of primary antibodies for tissue specimens. Speciﬁcity was
further conﬁrmed by Western blot analyses of cell lysates
and visualization of the corresponding protein bands at the
appropriate molecular weights for the respective antibodies
(data not shown).
2.3. Statistical Analyses. Statistical analysis of staining for
S3F, NP-1, and NP-2 among clinical samples was analyzed
by Spearman rank correlation and Fisher exact test for dif-
ferences in staining intensity and histological type. ANOVA
analyses were performed to determine signiﬁcant diﬀerences
in percentage of positively stained epithelia between N,
N combined with FT, Cy, and cancer (WD combined
with PD) groups. Spearman and Fisher exact tests were
performed with SAS version 9.2 (SAS Institute, Cary, NC)
and ANOVA tests were performed with Microsoft Excel
(Microsoft,Redmond,WA).P-values< 0.05wereconsidered
statistically signiﬁcant.
3. Results
3.1. S3F Expression Decreases with Epithelial Ovarian Cancer
Progression. W h e na l lh i s t o l o g i c a ls u b t y p e sw e r ec o n s i d e r e d ,
the expression level of S3F in epithelial cells was relativelyObstetrics and Gynecology International 3
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Figure 1: S3F expression decreases while NP-1 increases with epithelial ovarian cancer progression. Representative illustrations of
immunohistochemical staining of normal (N), serous cystadenoma (Cy), well-diﬀerentiated (WD) and poorly diﬀerentiated (PD) serous
adenocarcinomas) for S3F, NP-2, and NP-1. Placental tissue was used for positive control (C) and arrow indicates expression of S3F by
endothelial cells. Primary antibodies were replaced with non-immune serum in negative control sections (inset). Original magniﬁcation:
400×.
weak and decreased with tumor progression. We found a
signiﬁcant inverse correlation between S3F staining intensity
and histology where 83.3% (10/12) of N, 80% (8/10) of
Cy, and 75% (3/4) of WD specimens expressed weak S3F
staining, whereas the majority of PD specimens, 67% (4/6),
completely lacked S3F expression (Figures 1 and 2)( P<
.0001). No diﬀerences were observed as function of stage.
Interestingly, when we evaluated the percentage of positive
epithelia in the sections expressing S3F a signiﬁcantly higher
percentage of normal OSE was immunoreactive compared to
Cy (P<. 001) and cancer (P<. 001) (Table 1). The staining
pattern throughout the tissue sections was predominantly
cytoplasmicthoughasmallportion(<20%)ofepithelialcells
demonstratedbasalmembranousstainingpatterninnormal,
benign, and well-diﬀerentiated carcinomas (Figure 1).
Stromal cells of all histological groups did not express
S3F with the exception of endothelial cells that, together
with positive control placental tissues, expressed S3F in a
cytoplasmic and membranous localization (Figure 1, arrow),
thus providing in our cohort an internal positive control
for S3F expression. Immunostaining was not observed in
negative control samples (Figure 1, inset).4 Obstetrics and Gynecology International
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Figure 2:GraphicaldepictionofS3F,NP-2,andNP-1expressionwithepithelialovariancancerprogression.Immunohistochemicallystained
sections of normal (N), serous cystadenomas (Cy), well-diﬀerentiated (WD) and poorly diﬀerentiated (PD) serous adenocarcinomas were
evaluated for expression of S3f, NP-2 and NP-1 and scored as negative, weak, moderate, or strong as described in Materials and Methods.
3.2.NP-2ExpressionDecreaseswithEpithelialOvarianCancer
Progression. NP-2 was generally weakly expressed in all
histological groups but the proportion of positive epithelial
cells signiﬁcantly decreased with tumor progression. The
expression of NP-2 in 33% (4/12), 20% (2/10), 50% (2/4),
33% (2/6) of N, Cy, WD, and PD was generally weak
(Figures 1 and 2) and with no signiﬁcant statistical diﬀer-
ence. In contrast to normal ovaries where 71.4% of OSE
positivelyexpressedNP-2,thepercentageofpositiveepithelia
was signiﬁcantly lower in Cy, WD and PD where onlyObstetrics and Gynecology International 5
Table 1: Epithelial expression of S3F and NP-2 decreases while NP-1 increases with ovarian epithelial tumor progression.
S3F NP-2 NP-1
N 67.5±1.6 71.4±3.0 80.5±1.4
Cy 42.9 ±2.34 8 .8 ±2.18 6 .5 ±1.8
∗P ≤ .001  P ≤ .05 ∗P ≤ .001  P ≤ .001 ∗P ≤ .001  P ≤ .001
WD 21.6 ±3.91 9 .2 ±4.4 100
∗∗P ≤ .001 ◦P ≤ .05 ∗∗P ≤ .001 ◦P ≤ .001 ∗∗P ≤ .001 ◦P ≤ .001
PD 29.5 ±1.51 7 .1 ±2.3 100
∗∗P ≤ .001 ◦P ≤ .05 ∗∗P ≤ .001 ◦P ≤ .001 ∗∗P ≤ .001 ◦P ≤ .001
IC 100 100 100
PC 100 85.7 ±4.58 2 .5 ±2
FT 100 72.2 ±3.6 100
∗Nv e r s u sC y∗∗Nv e r s u sW D + P D N+F Tv e r s u sC y◦N + FT versus WD+PD. Abbreviations: normal (N), serous cystadenoma (Cy), well-diﬀerentiated
serous adenocarcinoma (WD), poorly diﬀerentiated serous adenocarcinoma (PD), inclusion cyst (IC), paraovarian cyst (PC), and fallopian tube (FT). Data
represent the average percent of positive epithelium expressing S3F, NP-2, and NP-1 ± SEM.
Figure 3: NP-2 expression occurs in distinct clusters of tumor cells.
Representative illustration of NP-2 expression in well-diﬀerentiated
serous adenocarcinoma (WD). Original magniﬁcation is 100× and
inset is 200×.
48.8%, 19.2%, and 17.1% were positive, respectively (P<
.001) (Table 1). The overall staining pattern was cytoplasmic
and membranous in all histological groups (Figure 1).
Interestingly, most cells expressing NP-2 in the examined
WD carcinomas were localized in highly distinctive clusters
within the tissue specimens of early stage compared to late
stage (Figure 3).
In contrast to epithelial cells, over 90% of stromal
cells in normal ovaries strongly expressed NP-2 (Figure 1).
Similar to normal tissue, stromal cells in Cy, WD, and PD
tissues expressed NP-2, however, the level of expression was
moderate (Figure 1). Like S3F, all endothelial cells within the
stroma and positive control placental tissues expressed NP-2
immunostaining.
3.3. NP-1 Expression Increases with Epithelial Ovarian Cancer
Progression. In contrast to S3F and NP-2, the overall expres-
sion of NP-1 increased signiﬁcantly with tumor progression.
Most (93.8%, 30/32) of the tissues examined expressed NP-
1( Figure 2). The overall staining intensity of NP-1 in N
and Cy sections ranged from weak, 58% (7/12) and 60%
(6/10),tomoderate,25%(3/12)and30%(3/10),respectively
(Figures 1 and 2, Table 1). In contrast, the vast majority
of cancerous tissues, 75% (3/4) of WD and 83% (5/6) of
PD samples, strongly expressed NP-1 (Figures 1 and 2);
however, no diﬀerences were observed as function of stage.
The percentage of positive epithelial cells also signiﬁcantly
increased as 80.5%, 86.5%, and 100% of epithelia were
positive for NP-1 in N, Cy and cancer tissues, respectively,
(Table 1).
Most stromal cells in N and Cy tissues expressed NP-1,
although the staining intensity was less than for NP-2.
Stromal staining was less in cancerous than in N and Cy
tissues (not shown).
3.4. S3F, NP-2, and NP-1 Expression is Elevated in Inclusion
Cysts, Paraovarian Cysts, and Fallopian Tube Epithelium.
Given the uncertain cellular origin of EOC, coelomic versus
extrauterine M¨ ullerian, we also evaluated the immunohis-
tochemical expression of S3F, NP-2, and NP-1 in ICs, PCs,
and FT tissues. We found an elevated staining intensity
and percentage of epithelial cells expressing S3F and its
receptors in ICs, PCs, and FT sections when compared to
normal ovarian and cancerous tissues (Figures 4 and 5,
Table 1).IncontrasttoWDandPDtissueswhereonly21.6%
and 29.5% of the epithelium were positive, 100% of the
epithelium lining the ICs expressed S3F (Table 1). All PCs
and FT epithelia expressed S3F either moderately or strongly
(Figures 4 and 5, Table 1). Similar to the normal ovary, only
endothelial cells, but no other surrounding stromal cells
expressed S3F.
NP-2 expression but not intensity was comparable to S3F
in epithelial cells of ICs and PCs (Figures 4 and 5, Table 1).
In contrast to WD and PD where only 19.2% and 17.1%
of the epithelial cells were positive for NP-2, respectively,
100%, 85.7%, and 72.2% of the epithelia lining ICs, PCs, and
FT, respectively, were positive (Table 1). In contrast to the
strongly staining stromal cells of the normal ovary, weak NP-
2 stromal staining was found in FT and PCs. All endothelial
cells were strongly immunoreactive for NP-2.6 Obstetrics and Gynecology International
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Figure 4: S3F expression is elevated in inclusion cysts, paraovarian cysts, and fallopian tubes. Representative illustrations of
immunohistochemical staining of normal ovary (N), inclusion cyst (IC), paraovarian cyst (PC), and fallopian tube (FT) for S3F, NP-2,
and NP-1. Original magniﬁcation is 400×.
Epithelial expression of NP-1 in ICs, PCs, and FT was
universal (Table 1) and similar to cancerous tissues; in
contrast to normal ovaries, 50%, 50%, and 25%, respectively
of IC, PC, and FT epithelia exhibited strong NP-1 staining
(Figures 4 and 5). Similar to NP-2, stromal cells displayed
negative to weak NP-1 expression while all endothelial cells
were positive.
4. Discussion
Loss or delocalization of S3F has been shown to correlate
with advanced tumor stage in lung cancer [21, 22]. In
this study, we sought to determine the clinical relationship
betweenS3Fandepithelialovariancancerprogression.Over-
all, we observed a signiﬁcant decrease in both intensity and
frequency of S3F staining with EOC progression. Although,
tumors of high grade and advanced stage expressed the least
amount of S3F, tumor grade was the only parameter that
indicated a signiﬁcant relationship between S3F expression
and EOC progression in this initial cohort of patients. Levels
of semaphorin 3A have also been reported to be signiﬁcantly
r e d u c e di na d v a n c e dE O Ca n dm e t a s t a s e s[ 23]. Taken
together, these ﬁndings suggest that the loss or deregulation
of semaphorin signaling may play an important role in EOC
progression and support a tumor suppressor function for
this molecule [17].
In contrast, the S3F receptors NP-2 and NP-1 have been
reported to be over-expressed in some cancers, including
ovarian cancer [22, 23]. In agreement with previous reports,
we found that the staining intensity and percentage of
epitheliumexpressingNP-1signiﬁcantlyincreasedwithEOC
progression and predominantly cytoplasmic. However, we
foundthatNP-2expressiondecreasedwithEOCprogression.
Diﬀerences in these results compared to other reportedObstetrics and Gynecology International 7
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Figure 5: Graphical depiction of S3F, NP-2, and NP-1 expression in inclusion cysts, paraovarian cysts, and fallopian tubes compared to
normal ovaries. Immunohistochemically stained sections of normal ovary (N), inclusion cysts (IC), paraovarian cysts (PC) and fallopian
tubes (FT) were evaluated for staining intensity and designated as negative, weak, moderate, or strong following staining with antibodies
directed against S3F, NP-2, and NP-1.
ﬁndings may reﬂect methodological diﬀerences in sample
preparation, scoring of immunostaining, and case distri-
bution. Interestingly, we observed prominent staining of
NP-2 in isolated, but highly distinct clusters of tumor
cells in early stage and low-grade (WD) ovarian cancer
tissues similar to that described by Brambilla et al. [21]i n
non-small cell lung cancer. These observations, in addition
to the cytoplasmic localization of receptors we observed8 Obstetrics and Gynecology International
and previously reported in both lung and ovarian cancers
[22, 23], further support a role for a S3F-NP pathway in
epithelial cell adhesion and/or migration.
Carcinomas arising from the ovary, fallopian tube, and
peritoneum have histological and clinical similarities [3].
Histological similarities with epithelia lining ICs, PCs, and
FT have also been documented [3] and explained on the
basis of common coelomic or M¨ ullerian system origin [4].
In the present study, while there was only weak expression
of S3F and NP-2 in EOC, OSE, and IC there was strong
expression of NP-1 in FT, PC, and EOC. This shared
phenotype indirectly supports a common M¨ ullerian origin
for epithelial ovarian cancer. Given the slightly younger
premenopausal age of normal individuals compared to the
peri- to postmenopausal age of benign and ovarian cancer
patients, a potential contribution of menopausal status on
S3F expression cannot be ruled out. Although in this initial
series, there was no noticeable diﬀerence in S3F expression
among normal specimens, additional studies are needed to
further evaluate independency from hormonal status.
Inconclusion,ourdatasuggeststhattheS3F-NPpathway
may be deregulated in EOC pathogenesis. Further investiga-
tion of S3F and its receptors in epithelial ovarian cancer is
warranted to delineate the molecular pathway(s) by which
suchderegulationmaypromotetumorprogressionand,ifso,
providenovelmoleculartargetsfortherapeuticintervention.
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